
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
The American Journal of Managed Care
about 23 years ago
Barriers to Mental Health Referral From Pediatric Primary Care Settings




